etodolac has been researched along with Inflammation in 8 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Case studies of hindlimbs from normal, adjuvant arthritic, and etodolac-treated arthritic rats demonstrated the association of disease severity with inflammation, chondromalacia, replacement of adipose bone marrow with a fibroid marrow, osteoclastic bone resorption, synovial cysts, and pannus formation within the joints." | 3.67 | Prostaglandins in inflammatory bone pathology: mechanism and therapeutic benefit of etodolac. ( Hayward, MA; Howard, GA; Neuman, RG; Van Sickle, DC; Weichman, BM; Wood, DD, 1989) |
| "The goal of this study was to look for correlations between the severity of chronic inflammatory joint disease and pharmacokinetic parameters of nonsteroidal antiinflammatory drugs." | 2.68 | Influence of severity of chronic inflammatory joint disease on the pharmacokinetics of indomethacin and etodolac. ( Goasguen, J; Guggenbuhl, P; Jacquelinet, C; Lapicque, F; Le Dantec, P; Netter, P; Pawlotsky, Y; Perdriger, A; Veillard, E, 1996) |
| "Etodolac was also capable of reducing the macrophage ability to migrate towards a chemoattractant." | 1.27 | The effect of the non-steroidal anti-inflammatory drug Etodolac on macrophage migration in vitro and in vivo. ( Gervais, F; Martel, RR; Skamene, E, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Hirono, J | 1 |
| Sanaki, H | 1 |
| Kitada, K | 1 |
| Sada, H | 1 |
| Suzuki, A | 1 |
| Lie, LK | 1 |
| Segi-Nishida, E | 1 |
| Nakagawa, K | 1 |
| Hasegawa, H | 1 |
| Iwata, C | 1 |
| Kano, MR | 1 |
| Komuro, A | 1 |
| Oka, M | 1 |
| Kiyono, K | 1 |
| Johansson, E | 1 |
| Morishita, Y | 1 |
| Yashiro, M | 1 |
| Hirakawa, K | 1 |
| Kaminishi, M | 1 |
| Miyazono, K | 1 |
| Narita, M | 1 |
| Shimamura, M | 1 |
| Imai, S | 1 |
| Kubota, C | 1 |
| Yajima, Y | 1 |
| Takagi, T | 1 |
| Shiokawa, M | 1 |
| Inoue, T | 1 |
| Suzuki, M | 1 |
| Suzuki, T | 1 |
| Gervais, F | 1 |
| Martel, RR | 1 |
| Skamene, E | 1 |
| Laine, L | 1 |
| Cominelli, F | 1 |
| Sloane, R | 1 |
| Casini-Raggi, V | 1 |
| Marin-Sorensen, M | 1 |
| Weinstein, WM | 1 |
| Pawlotsky, Y | 1 |
| Le Dantec, P | 1 |
| Jacquelinet, C | 1 |
| Lapicque, F | 1 |
| Goasguen, J | 1 |
| Perdriger, A | 1 |
| Veillard, E | 1 |
| Guggenbuhl, P | 1 |
| Netter, P | 1 |
| Hayward, MA | 1 |
| Howard, GA | 1 |
| Neuman, RG | 1 |
| Wood, DD | 1 |
| Weichman, BM | 1 |
| Van Sickle, DC | 1 |
2 trials available for etodolac and Inflammation
| Article | Year |
|---|---|
Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Etodolac; Gas | 1995 |
Influence of severity of chronic inflammatory joint disease on the pharmacokinetics of indomethacin and etodolac.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Ar | 1996 |
6 other studies available for etodolac and Inflammation
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Expression of tissue inhibitor of metalloproteinases and matrix metalloproteinases in the ischemic brain of photothrombosis model mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Disease Models, Animal; Endothelia | 2018 |
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etodolac; Humans; Inflammation; Lymphangioge | 2007 |
Role of interleukin-1beta and tumor necrosis factor-alpha-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relation | 2008 |
The effect of the non-steroidal anti-inflammatory drug Etodolac on macrophage migration in vitro and in vivo.
Topics: Acetates; Animals; Anti-Inflammatory Agents; Cell Movement; Chemotaxis; Etodolac; In Vitro Technique | 1984 |
Prostaglandins in inflammatory bone pathology: mechanism and therapeutic benefit of etodolac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Experimental; Bone and Bones | 1989 |